tetano
Editor, Senior Moderator
Front Cell Infect Microbiol
. 2022 Jan 18;11:781429.
doi: 10.3389/fcimb.2021.781429. eCollection 2021.
SARS-COV-2 Variants: Differences and Potential of Immune Evasion
Sandro M Hirabara[SUP] 1 [/SUP], Tamires D A Serdan[SUP] 2 [/SUP], Renata Gorjao[SUP] 1 [/SUP], Laureane N Masi[SUP] 1 [/SUP], Tania C Pithon-Curi[SUP] 1 [/SUP], Dimas T Covas[SUP] 3 4 [/SUP], Rui Curi[SUP] 1 5 [/SUP], Edison L Durigon[SUP] 6 7 [/SUP]
Affiliations
Abstract
The structural spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) plays an essential role in infection and is an important target for neutralizing antibody recognition. Mutations in the S gene can generate variants of concern (VOCs), which improve "viral fitness" through selective or survival advantages, such as increased ACE-2 receptor affinity, infectivity, viral replication, higher transmissibility, resistance to neutralizing antibodies and immune escape, increasing disease severity and reinfection risk. Five VOCs have been recognized and include B.1.1.7 (U.K.), B.1.351 (South Africa), P.1 (Brazil), B.1.617.2 (India), and B.1.1.529 (multiple countries). In this review, we addressed the following critical points concerning VOCs: a) characteristics of the SARS-CoV-2 VOCs with mutations in the S gene; b) possible evasion of variants from neutralizing antibodies generated through vaccination, previous infection, or immune therapies; c) potential risk of new pandemic waves induced by the variants worldwide; and d) perspectives for further studies and actions aimed at preventing or reducing the impact of new variants during the current COVID-19 pandemic.
Keywords: COVID-19; delta variant; immune escape; neutralizing antibody; omicron variant; vaccines; variant of concern.
. 2022 Jan 18;11:781429.
doi: 10.3389/fcimb.2021.781429. eCollection 2021.
SARS-COV-2 Variants: Differences and Potential of Immune Evasion
Sandro M Hirabara[SUP] 1 [/SUP], Tamires D A Serdan[SUP] 2 [/SUP], Renata Gorjao[SUP] 1 [/SUP], Laureane N Masi[SUP] 1 [/SUP], Tania C Pithon-Curi[SUP] 1 [/SUP], Dimas T Covas[SUP] 3 4 [/SUP], Rui Curi[SUP] 1 5 [/SUP], Edison L Durigon[SUP] 6 7 [/SUP]
Affiliations
- PMID: 35118007
- PMCID: PMC8805732
- DOI: 10.3389/fcimb.2021.781429
Abstract
The structural spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) plays an essential role in infection and is an important target for neutralizing antibody recognition. Mutations in the S gene can generate variants of concern (VOCs), which improve "viral fitness" through selective or survival advantages, such as increased ACE-2 receptor affinity, infectivity, viral replication, higher transmissibility, resistance to neutralizing antibodies and immune escape, increasing disease severity and reinfection risk. Five VOCs have been recognized and include B.1.1.7 (U.K.), B.1.351 (South Africa), P.1 (Brazil), B.1.617.2 (India), and B.1.1.529 (multiple countries). In this review, we addressed the following critical points concerning VOCs: a) characteristics of the SARS-CoV-2 VOCs with mutations in the S gene; b) possible evasion of variants from neutralizing antibodies generated through vaccination, previous infection, or immune therapies; c) potential risk of new pandemic waves induced by the variants worldwide; and d) perspectives for further studies and actions aimed at preventing or reducing the impact of new variants during the current COVID-19 pandemic.
Keywords: COVID-19; delta variant; immune escape; neutralizing antibody; omicron variant; vaccines; variant of concern.